NOTIFICATION TO STOCK EXCHANGE
Company Statement
Bengaluru, Karnataka, India, Aug 31, 2019
“The U.S. FDA conducted a cGMP inspection at one of our Biologics Drug Product facilities in Bengaluru from Aug 22 to Aug 30, 2019. The inspection concluded with four observations which we believe will not impact supplies from this facility. We are confident of addressing these observations through a Corrective and Preventive Action plan in a timely manner.”
– Company Spokesperson
Download Company Statement